Bio Key International (BKYI): Chief Technology Officer received 2,500 shares
Mira K Lacous, Chief Technology Officer at Bio Key International, reported a grant / award of 2,500 shares.
- 2,500
- Shares · @ $0.46
- Traded
- Dec 31, 2025
- Filed
- Jan 6, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 6, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on May 9, 2025, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company did not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”), as the Company’s closing bid price was less than $1.00…”
- Nov 14, 2025Company filing · Form 8-K · ResultsReported its results
What came next
- Mar 3, 2026Company filing · Form 8-K · ResultsReported its results
- Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 16, 2026Company filing · Form 8-K · Listing notice, Reg FDReceived a notice from its stock exchange, and shared information with investors“On April 16, 2026, BIO-key International, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market, LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company’s failure to timely file its Annual Report on Form 10-K for the…”
- Apr 28, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Bio Key International
OQRO holds no insider, Congress, fund or contract record for Bio Key International dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BKYI page.
How this filing works
Explore the data
Common questions
Which Bio Key International (BKYI) insider traded, and how much?
Mira K Lacous, Chief Technology Officer at Bio Key International, reported a grant / award of 2,500 shares. At $0.46.
When did it happen, and when was it made public?
Traded: Dec 31, 2025. Filed: Jan 6, 2026. That is 6 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean BKYI stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Bio Key International
- SEC Form 4Sep 17, 2025
- SEC Form 4Sep 17, 2025
- SEC Form 4Aug 27, 2025
- SEC Form 4Jun 16, 2025
- SEC Form 4Jun 4, 2025
- SEC Form 4Jun 3, 2025
Everything OQRO holds on this company is on its BKYI page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
